Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).

Autor: Kunz PL; Yale School of Medicine, New Haven, CT., Graham NT; Dana-Farber Cancer Institute, Boston, MA., Catalano PJ; Dana-Farber Cancer Institute, Boston, MA., Nimeiri HS; Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL., Fisher GA; Stanford University School of Medicine, Stanford, CA., Longacre TA; Stanford University School of Medicine, Stanford, CA., Suarez CJ; Stanford University School of Medicine, Stanford, CA., Martin BA; University of Louisville, Louisville, KY., Yao JC; University of Texas MD Anderson Cancer Center, Houston, TX., Kulke MH; Boston University/Boston Medical Center, Boston, MA., Hendifar AE; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA., Shanks JC; Health East Cancer Care, Lake Elmo, MN., Shah MH; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Zalupski MM; University of Michigan, Ann Arbor, MI., Schmulbach EL; The Permanente Medical Group, South San Francisco, CA., Reidy-Lagunes DL; Weill Cornell Medical College, New York, NY., Strosberg JR; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL., O'Dwyer PJ; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA., Benson AB 3rd; Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Mar 01; Vol. 41 (7), pp. 1359-1369. Date of Electronic Publication: 2022 Oct 19.